Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patient health. The company’s medicines address the unmet medical needs of patients in the areas of anti-HIV treatment and pain management. It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS. The company’s products in development include FB1002, an all-injectable long-acting HIV therapy; FB2001, a SARS-CoV-2 3CL protease inhibitor under clinical development for hospitalized patients as well as for post-exposure prophylaxis of Covid-19; FB3001, a new transdermal topical patch for musculoskeletal joint pain treatment under clinical development; and FB600, an investigational therapeutic peptide vaccine targeting PCSK9 to treat hypercholesterolemia. The company was founded in 2013 and is headquartered in Nanjing, China.